CollPlant Biotechnologies Ltd. (CLGN)

NASDAQ: CLGN · IEX Real-Time Price · USD
11.56
+0.72 (6.64%)
Feb 1, 2023, 10:29 AM EST - Market open
6.64%
Market Cap 126.30M
Revenue (ttm) 551,000
Net Income (ttm) -16.30M
Shares Out 11.19M
EPS (ttm) -1.45
PE Ratio n/a
Forward PE 4.92
Dividend n/a
Ex-Dividend Date n/a
Volume 6,619
Open 10.79
Previous Close 10.84
Day's Range 10.50 - 11.57
52-Week Range 4.27 - 14.77
Beta 0.69
Analysts Buy
Price Target 17.34 (+50.0%)
Earnings Date Mar 22, 2023

About CLGN

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 66
Stock Exchange NASDAQ
Ticker Symbol CLGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for CLGN stock is "Buy." The 12-month stock price forecast is $17.34, which is an increase of 50.00% from the latest price.

Price Target
$17.34
(50.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CollPlant Issues Letter to Shareholders

REHOVOT, Israel , Jan. 24, 2023 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and org...

1 week ago - PRNewsWire

CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives

Study demonstrated progressive stages of tissue regeneration as highlighted by the formation of maturing connective tissue and neovascular networks within the implants No indication of adverse reactio...

1 month ago - PRNewsWire

CollPlant Enriches Portfolio of rhCollagen-Based Bioinks with Launch of Collink.3DTM 50L in Powder Form

Company's first bioink available in powder form provides enhanced operational flexibility to support a wide range of 3D bioprinting applications Collink.3D™ 50L strengthens CollPlant's platform of bio...

1 month ago - PRNewsWire

CollPlant Biotechnologies Provides Business Updates and Third Quarter 2022 Financial Results

Partnership with AbbVie to co-develop rhCollagen-based dermal and soft tissue fillers continues to advance according to plan Co-developing 3D bioprinted human intestine model ("Gut-on-a-Chip") for dru...

2 months ago - PRNewsWire

CollPlant, Tel Aviv University and Sheba Medical Center Join Forces to Co-Develop rhCollagen-Based 3D Bioprinted Human Intestine Model for Drug Discovery and Personalized Treatment of Ulcerative Colitis

Agreement to accelerate development of a 'Gut-on-a-Chip' tissue model to improve therapeutic choice and outcome of ulcerative colitis patients CollPlant to fund development and receive exclusive licen...

2 months ago - PRNewsWire

CollPlant Expands rhCollagen-Based Bioink Platform with Launch of Collink.3D™ 90

Collink.3D™ 90 offers additional functionality to address wide range of 3D bioprinting applications, including soft and hard tissues Collink.3D™ 90 demonstrates faster human cell migration into gel ma...

3 months ago - PRNewsWire

CollPlant to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 17

REHOVOT, Israel , Nov. 3, 2022 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative human-collagen based technologies and prod...

3 months ago - PRNewsWire

CollPlant to present at the Dawson James Small Cap Growth Conference on October 12

REHOVOT, Israel , Oct. 3, 2022 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regen...

4 months ago - PRNewsWire

CollPlant to Present at the International Conference on Biofabrication 2022 in Tuscany, Italy

REHOVOT, Israel , Sept. 19, 2022 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative human collagen-based technologies and products for tissu...

4 months ago - PRNewsWire

CollPlant Biotechnologies to Participate in September Investor Conferences

REHOVOT, Israel , Sept. 6, 2022 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and prod...

5 months ago - PRNewsWire

CollPlant Biotechnologies Provides Business Updates and Second Quarter 2022 Financial Results

Co-development of rhCollagen-based dermal and soft tissue fillers with AbbVie is progressing Company's 3D bioprinted regenerative breast implant program remains on track to conclude large animal study...

5 months ago - PRNewsWire

CollPlant to Present and Exhibit at TERMIS Annual Conference in Toronto, Canada

At the Tissue Engineering and Regenerative Medicine International Society conference, CollPlant will deliver a presentation 'rhCollagen - The Ideal Building Block For 3D Printed and Injectable Scaffol...

7 months ago - PRNewsWire

CollPlant Advances its 3D Bioprinted Regenerative Breast Implants into Porcine Study

rhCollagen-based regenerative breast implants address $2.8 billion global breast implant market with revolutionary and potentially safer new product Regenerative breast implants for aesthetic and reco...

7 months ago - PRNewsWire

CollPlant Biotechnologies Provides Business Updates and First Quarter 2022 Financial Results

Co-development of rhCollagen-based dermal and soft tissue filler products with AbbVie is advancing according to plan Launch of large animal study for Company's 3D bioprinted regenerative breast implan...

8 months ago - PRNewsWire

CollPlant CEO Yehiel Tal to Moderate ISBF's virtual event on Biofabrication of Microphysiological Systems for Drug Discovery and Screening

REHOVOT, Israel , April 25, 2022 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and or...

10 months ago - PRNewsWire

New Strong Sell Stocks for April 22nd

BBBY, CLGN, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 22, 2022

Other symbols: ADAPBBBY
10 months ago - Zacks Investment Research

CollPlant To Present at the Aesthetics Innovation Summit 2022

REHOVOT, Israel , April 13, 2022 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and or...

10 months ago - PRNewsWire

CollPlant Biotechnologies Provides Business Updates and Fiscal Year 2021 Financial Results

REHOVOT, Israel, March 24, 2022 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regen...

11 months ago - PRNewsWire

CELLINK and CollPlant Enter a Collaboration Agreement to Explore Future Large-Scale Production of CollPlant's Regenerative Breast Implants using CELLINK's Bioprinting technologies

GOTHENBURG, Sweden and REHOVOT, Israel, Feb. 16, 2022 /PRNewswire/ -- Today, CELLINK, a BICO Group company (Nasdaq Stockholm: BICO) and a global leader in developing 3D bioprinting technologies which ...

1 year ago - PRNewsWire

CollPlant Announces Publication Highlighting its rhCollagen-based Photocurable Dermal Filler in the Plastic and Reconstructive Surgery Journal

Preclinical modeling demonstrates potential for filler to enhance cell proliferation and new tissue regeneration for aesthetic medicine applications REHOVOT, Israel, Dec. 2, 2021 /PRNewswire/ -- CollP...

1 year ago - PRNewsWire

CollPlant Biotechnologies Provides Business Updates and Third Quarter 2021 Financial Results

REHOVOT, Israel, Nov. 18, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regene...

1 year ago - PRNewsWire

CollPlant Announces Commercial Launch of BioInk Platform with Collink.3D™ for Use in 3D Bioprinting of Human Tissues, Scaffolds and Organs

REHOVOT, Israel, Nov. 15, 2021 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regen...

1 year ago - PRNewsWire

CollPlant to Present at Dawson James Small Cap Growth Conference on October 21st

REHOVOT, Israel, Oct. 14, 2021 /PRNewswire/ - CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regene...

1 year ago - PRNewsWire

CollPlant's rhCollagen BioInk Used by Technion Researchers to Develop 3D Bioprinted Vascularized Tissue Constructs

REHOVOT, Israel, Oct. 11, 2021 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regen...

1 year ago - PRNewsWire

CollPlant to Present at Fall Harvest - Best Ideas from the Buy-Side on October 5, 2021

REHOVOT, Israel, Sept. 30, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue rege...

1 year ago - PRNewsWire